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Background: The reported effects of flavanol-rich foods such as cocoa, dark 2 
chocolate and apples on blood pressure and endothelial function may be due 3 
to the monomeric flavanols (mainly (-)-epicatechin (EC)), the oligomeric 4 
flavanols (procyanidins; PC) or other components. Reports of well controlled 5 
intervention studies that test the effects of isolated oligomeric flavanols on 6 
biomarkers of cardiovascular health are lacking.  7 
Objective: We studied the acute and chronic effects of an EC-rich apple 8 
flavanol extract and isolated apple PCs on systolic BP and other 9 
cardiometabolic biomarkers. 10 
Design: Forty-two healthy men and women with moderately elevated BP 11 
completed this randomized double-blind, placebo-controlled, four arm 12 
crossover trial. Participants ingested a single dose of an apple flavanol extract 13 
(70 mg monomeric flavanols, 65 mg PC), a double dose of this extract (140 14 
mg monomeric flavanols, 130 mg PC), an apple PC extract (130 mg PC, 6.5 15 
mg monomeric flavanols) or placebo capsules once daily for 4 weeks, in 16 
random order. Biomarkers of CVD risk and vascular function were measured 17 
before and 2h after ingestion of the first dose, and after 4 weeks intervention.  18 
Results: Compared to the placebo, none of the isolated flavanol treatments 19 
significantly (p<0.05) changed SBP or DBP (peripheral and aortic), plasma 20 
NO reaction products or measures of arterial stiffness (cf_PWV, ba_PWV and 21 
AI) after 2 h or 4 weeks of intervention. There were no changes in plasma 22 
endogenous metabolite profiles, or circulating NO, endothelin-1, total-, HDL-, 23 
LDL-cholesterol, TAGs, fasting glucose, fructosamine and insulin after 4 24 
weeks of intervention.  25 
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Conclusions: Our data suggest that in isolation, neither monomeric flavanols 26 
or PC affect BP, blood lipid profiles, endothelial function or glucose control in 27 
individuals with moderately elevated blood pressure. The reported benefits of 28 
consuming flavanol-rich cocoa, chocolate and apple products appears to be 29 





Monomeric flavanols such as epicatechin (EC) and their oligomeric derivatives 33 
(procyanidins; PC) are a sub-class of the flavonoids that are widely available as part of 34 
the human diet. Some epidemiological studies have reported an inverse correlation 35 
between the consumption of flavanol-rich foods and cardiovascular disease (CVD) (1-36 
3). These observations are substantiated by several meta-analyses of human 37 
intervention trials demonstrating that acute and chronic ingestion of flavanol-rich foods 38 
and beverages such as dark chocolate, cocoa products and apples causes decreases 39 
in blood pressure (BP) in both healthy, normotensive individuals and hypertensive 40 
patients (4-6), reductions in serum insulin (7) and improvements in circulating lipid 41 
profiles (4, 8). Similarly, some studies have demonstrated significant reductions in 42 
fasting blood glucose (9) as well as improvements in markers of vascular function 43 
such as endothelial-derived nitric oxide (NO) (10-12), endothelin-1 (ET-1) (10) and 44 
pulse wave velocity (PWV) (13, 14), a measure of arterial stiffness and an emerging 45 
marker of CVD risk. 46 
 The main food sources studied for their BP-lowering properties are flavanol-rich 47 
cocoa products, tea and apples. Meta-analyses of randomized controlled trials (RCTs) 48 
reported that repeated daily ingestion of chocolate and cocoa beverages over 2-18 49 
weeks significantly reduced systolic BP (SBP) and diastolic BP (DBP) by 5.9 mmHg 50 
and 3.3 mmHg (4) and by 4.5 and 2.5 mmHg (6).   51 
 Evidence as to whether or not the cardio-protective effects observed in 52 
intervention studies with cocoa/chocolate and other flavanol-rich foods/extracts are 53 
due to the EC monomer is inconsistent (12, 15-17). For example, Schroeter et al. 54 
published data from human dietary intervention studies and mouse aortic ring 55 
relaxations experiments with cocoa flavanols and isolated EC and concluded that EC 56 
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was responsible for the beneficial effects of cocoa flavanols on endothelial function 57 
(12), whereas other studies have reported no significant effects of a similar dose of 58 
isolated EC on endothelial function in humans (20).  Even though PC have been 59 
shown to possess potent biological activity in vitro (17, 18), we are not aware of any 60 
studies that have assessed the effects of isolated PC (i.e. depleted of flavanol 61 
monomers) on blood pressure in humans.  62 
 The aim of this study was to investigate the effects of isolated flavanols on BP 63 
and other biomarkers of cardiometabolic health. To achieve this, we used (i) an EC-64 
rich flavanol extract derived from flavanol-rich apples for which we have previously 65 
reported the bioavailability of EC and shown it to be similar to that for cocoa products 66 
(19), and (ii) an apple PC extract that was depleted of monomeric flavanols. The apple 67 
flavanol extracts are devoid of other bioactive substances found in cocoa extracts 68 
such as the methylxanthines. We report the effects of the EC-rich flavanol extract at 69 
two doses and the effects of a PC rich extract depleted of monomeric flavanols versus 70 
a placebo control. To assess the broader effects of flavanols on host metabolism, we 71 
also report, to our knowledge for the first time, the effects of the treatments on plasma 72 
metabolite profiles using a non-targeted LC-MS based platform that allows relative 73 
quantification of several hundred metabolites, the majority being host metabolites.  74 
 75 
SUBJECTS AND METHODS 76 
 77 
Study population 78 
Forty-three, apparently healthy men and women aged 50+ years with a SBP 79 
between 120 and 159 mmHg at eligibility assessment were recruited in and around 80 
Norwich, UK. Office SBP was measured by a research nurse using an automated BP 81 
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monitor (Omron).  The exclusion criteria were as follows: smoking; medical 82 
conditions such as gastrointestinal disease, diabetes, cancer, heart disease, stroke; 83 
HRT (unless stable on therapy for a period of at least 6 months); medications judged 84 
to affect the trial outcome such as blood pressure and lipid lowering therapy; some 85 
dietary supplements (e.g. fish oils); clinical results at eligibility assessment judged to 86 
affect the trial outcome or be indicative of a health problem. The study period was 87 
from August 2014 to March 2016. The trial was conducted in the Human Nutrition 88 
Unit at the Quadram Institute Bioscience, Norwich, UK (formerly Institute of Food 89 
Research) and all procedures were approved by both the Human Research 90 
Governance Committee of the Quadram Institute Bioscience and the Norfolk 91 
Research Ethics Committee. Each participant gave written informed consent prior to 92 
taking part in the trial. The trial is registered with clinicaltrials.gov (Ref: 93 
NCT02013856).  94 
 95 
Study design 96 
The study was a randomized, double-blind, placebo-controlled four arm crossover 97 
trial investigating the acute and chronic effects of apple derived flavanols on risk 98 
markers for CVD (Figure 1). The four treatments were: (i) an apple extract delivering 99 
70 mg monomeric flavanols and 65 mg PC (low dose), (ii) an apple extract delivering 100 
140 mg monomeric flavanols and 130 mg PC (high dose), (iii) an apple extract 101 
depleted of monomeric flavanols but containing 130 mg PC, and (iv) a placebo 102 
control. Apple extracts and placebo (microcrystalline cellulose) were delivered in 103 
opaque, cellulose based capsules suitable for oral consumption and which release 104 
their contents within 15 minutes of reaching the stomach (K-caps vegetarian 105 
capsules; GoCap).  106 
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The primary outcome measure for this trial was SBP. Secondary outcome 107 
measures were biomarkers of endothelial function and cardiometabolic risk including 108 
blood lipids (total cholesterol, HDL/LDL cholesterol and TAG), glucose, insulin, 109 
fructosamine, ET-1, plasma NO reaction products, and measures of arterial stiffness 110 
(cf_PWV, ba_PWV and AI). 111 
 The apple extracts and placebo were encapsulated and bottled before the start 112 
of the trial, with all capsules having identical appearance. The encapsulated 113 
flavanols were shown to remain stable throughout the study by regular analysis of 114 
sample capsule contents for monomeric and oligomeric flavanols using a validated 115 
method (20). The four treatments were randomly allocated as A, B, C or D by a 116 
designated person not assigned to the trial. The order in which the participants 117 
ingested the treatments was determined by a computer generated 118 
(randomization.com) sequence of letters from A-D using a block randomisation 119 
approach. Participants meeting the eligibility criteria were allocated sequentially to a 120 
treatment sequence upon enrolment by the study manager. The participants, 121 
principal investigator, study manager, nurse, statistician and those assessing 122 
outcomes were blinded to the interventions; un-blinding was done once statistical 123 
analyses were complete. 124 
 Capsules (n=2) were ingested once daily (in the morning) for 28 d with a 125 
minimum two-week washout period between each of the treatments. To aid 126 
compliance, participants were provided with a capsule checklist and asked to record 127 
consumption of the capsules on each day. Compliance to treatment was assessed 128 
from the checklist and by counting the unused capsules returned at the end of the 129 
treatment period. For 24 h prior to the start of each treatment period and for the 28 d 130 
treatment period, participants were asked to exclude from their diets some food 131 
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sources that contribute significantly to total flavanol intake (e.g. dark 132 
chocolate/cocoa) and limit other food sources to levels that would support 133 
compliance (i.e. tea, berry fruits) or have known cardio-protective effects (e.g. oily 134 
fish). Foods on the limited list were completely excluded from the diet for 24 h prior 135 
to assessment days.  A list of prohibited and limited foods was provided to the 136 
participants to aid compliance. 137 
 Participants were assessed at the start and end of each 28 d treatment period. 138 
To investigate the chronic effects of flavanols on risk markers for CVD the following 139 
measurements were made on day 1 at 0 h (baseline) and day 29 of each treatment 140 
period: blood pressure (peripheral and aortic); arterial stiffness (ba_PWV; cf_PWV; 141 
AI); fasting blood samples were collected for the analysis of plasma flavanols; 142 
circulating levels of lipids/lipoproteins, glucose, fructosamine, insulin, NO reaction 143 
products and ET-1. To investigate the acute effects of flavanols on risk markers for 144 
CVD, BP, arterial stiffness and NO reaction products were re-assessed 2 h after 145 
ingestion of the capsules on day 1. This time point was chosen to coincide with 146 
expected peak plasma concentrations of flavanols and participants remained fasted 147 
until completion of the 2-h measurements.  148 
 149 
Apple extracts 150 
The apple extracts were produced from a crude apple juice by a combination of 151 
alcoholic extraction and chromatographic separation to generate i) an epicatechin-152 
rich extract containing around 30 % (w/w) of monomeric catechins (90% (‒)-EC, 10% 153 
(+)-catechin) that retained some of the PC and ii) an oligomeric PC rich extract that 154 
was significantly depleted of monomeric catechins. Both materials were produced 155 
from the same single crop of apples grown in Herefordshire, UK. Extracts were 156 
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analysed for monomeric and oligomeric catechins by HPLC-based separation using 157 
a HILIC stationary phase (Luna Hilic column 150 x 2.0 mm; 3µM) coupled with 158 
fluorescence detection as described previously (20). The flavanol composition of the 159 
three apple treatments is shown in Table 1. In addition, the apple extracts were 160 
shown to contain only the (-)-enantiomer of EC and the (+)-enantiomer of catechin 161 
using an HPLC column with a chiral stationary phase. The extracts contained minor 162 
quantities of other apple polyphenols as follows: Epicatechin-rich extract (low dose) - 163 
4.5 mg chlorogenic acid, 3.2 mg phloridzin, <1 mg quercetin glycosides; procyanidin-164 
rich extract – 11.8 mg chlorogenic acid, 10.3 mg phloridzin, 3.0 mg quercetin 165 
glycosides.  166 
 167 
Blood pressure assessment 168 
Office BP was measured using an automated BP monitor (Omron M6). 169 
Measurements were conducted in a quiet room after a 10 min period of rest with the 170 
participant in a semi-supine position and the arm resting at heart level. 171 
Measurements were conducted using the same designated arm (determined at 172 
eligibility assessment) for the duration of the entire study. Four consecutive readings 173 
were obtained at 5 min intervals, and the first reading discarded. 174 
 BP was also assessed using the validated Vicorder device (Smart Medical; 175 
Gloucester, UK). Peripheral SBP (pSBP) and peripheral DBP (pDBP) measurements 176 
were obtained in a similar manner to office BP. Aortic SBP (aSBP) and aortic DBP 177 
(aDBP) were derived from the peripheral BP and brachial pulse wave analysis from 178 
an in-built transfer function of the vicorder device. To minimize the effects of diurnal 179 
variation in BP, baseline and day 29 measurements were always conducted at the 180 
same time of day (07.30 – 08.00) for all participants.   181 
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   182 
Arterial stiffness assessments 183 
Cf_PWV, ba_PWV and AI were measured with participants in the semi-supine 184 
position (30º angle) using the vicorder device. To determine cf_PWV, an inflatable 185 
sensor (30 mm) was placed over the right carotid region and a BP cuff placed 186 
around the upper right thigh to measure the carotid and femoral pressure pulse 187 
waves, respectively. Path length was determined by measuring the distance (in cm) 188 
between the supra-sternal notch and the mid-point of the thigh cuff. The carotid 189 
sensor and thigh cuff were inflated (~ 60 mmHg) and waveforms simultaneously 190 
recorded over 10-15 consecutive heartbeats. To determine ba_PWV, BP cuffs were 191 
placed around the ankle and the right upper arm. Path length was determined by 192 
measuring the distance between the supra-sternal notch and the mid-point of the 193 
ankle cuff. Both cuffs were inflated and pressure waveforms simultaneously 194 
recorded.  195 
 196 
Biochemical markers for CVD 197 
Whole blood was collected into EDTA, heparin and serum separating tubes (Becton-198 
Dickenson). Samples collected into EDTA and heparin tubes were immediately 199 
centrifuged at 2500 x g for 10 mins. Samples collected in serum separating tubes 200 
were centrifuged after 30 minutes at 2000 x g for 10 mins. After centrifugation, 201 
plasma and serum were stored at -80 ºC until analysis.  202 
 203 
Plasma ET-1 and insulin status were determined using commercially available 204 
ELISA kits (R&D systems) according to the manufacturer’s instructions. Serum lipids 205 
(total/HDL/LDL cholesterol and TAG), glucose and fructosamine status were 206 
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determined using an automated clinical chemistry analyser (Randox; Daytona plus). 207 
The plasma concentration of NO reaction products (nitrate + nitrite + nitrosothiols) 208 
was determined using a Sievers 280i NO analyser (Sievers Instruments Inc) 209 
comprising of a purge vessel attachment, hot water bath to control the temperature 210 
of the reaction vessel and a chill bath to control the condenser. The 280i NOA 211 
reduces nitrite, nitrate and nitrosothiols to NO in the purge vessel which is then 212 
quantified according to the chemiluminescence signal released transiently within the 213 
instrument. Plasma samples were deproteinated with cold ethanol (1:2 dilutions) and 214 
centrifuged before analysis. Samples (20 µL) were injected onto the purge vessel 215 
and analysed in triplicate.  216 
  217 
Plasma metabolite profiles  218 
Identification of the plasma metabolites in d1 (baseline) and d29 samples was 219 
conducted by Metabolon USA (www.metabolon.com) using ultra-performance liquid 220 
chromatography (Waters ACQUITY)) and a high resolution mass spectrometer 221 
(Thermo Scientific) interfaced with a heated electrospray ionization source and 222 
orbitrap mass analyser operated at 35,000 mass resolution. A total of 671 relevant 223 
metabolites were identified. The classes of metabolites were: xenobiotics, lipids 224 
amino acids, nucleotides, peptides, carbohydrates, vitamins and catecholamines 225 
(see on-line supplemental Table 3 for a list of all metabolites). Values were 226 
normalized in terms of raw area counts, each metabolite rescaled to set the median 227 
equal to 1, and any missing values imputed with the minimum observed value for 228 
each compound. The average percentage missing values was 10.2% overall; 32.1% 229 
for xenobiotics, 5.9% for non-xenobiotics, and 4.5% for the dataset used for 230 




Analysis of epicatechin in plasma  233 
Plasma samples (200 µl) were mixed with 5 % aqueous trichloroacetic acid (200 µl) 234 
and dimethylformamide (200 µl). Taxifolin (10 µl; 10µg/mL) was added as an internal 235 
standard.  Samples were vortexed mixed before centrifugation at 17,000 g for 15 236 
min. Post centrifugation, samples were filtered (0.45 µm disposable filter) prior to 237 
UPLC-MS analysis. 238 
Samples were injected onto a Waters C18 column (100 mm × 2.1 mm; 1.7 239 
µM) connected to an Agilent 1200 LC system with the eluent passing through a 240 
diode array detector and a triple quadrupole mass spectrometer (Applied Biosystems 241 
6490, Ontario, Canada) and eluted at a flow rate of 0.4 ml/min. Elution was achieved 242 
using a gradient of increasing solvent B (acetonitrile and  0.1% acetic acid) from 243 
solvent A (water and 0.1% acetic acid) as follows: T = 0 min, solvent B = 5%; t = 0.5 244 
min, solvent B = 5%; t = 10 min, solvent B = 95%; t = 11 min, solvent B = 95%; t = 245 
11.1 min, solvent B = 5%  and t = 13 min, solvent B = 5%. The injection volume was 246 
1 µL. Catechin/EC metabolites were quantified against a (-)-EC standard over the 247 
range 10 – 1000 µg/mL. 248 
 249 
Statistical analysis  250 
The study was powered to detect a mean reduction in SBP of 4.1 mmHg at 90% 251 
power and with a significance level of 0.05, and the pre-study power calculation was 252 
based on SBP in a cohort of participants enrolled in a study conducted at University 253 
College Cork, Ireland. The calculations supported the recruitment of 39 participants 254 
in total. For the biomarkers of CVD risk, post – pre-differences between the four 255 
treatments were analysed using a non-parametric repeated measures ANOVA after 256 
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excluding subjects with an incomplete set of differences. All data are presented as 257 
means ± SD. 258 
Plasma metabolite data were analysed using multivariate methods were used to 259 
analyse the plasma metabolite data. For this, Xenobiotics and compounds for which 260 
more than half the values were missing (110 & 11 compounds, respectively) were 261 
removed, after checking the prevalence of missing values was not treatment specific.  262 
The resulting dataset (8 measurements per volunteer x 550 compounds, logged 263 
data) was analysed by Principal Component Analysis (PCA) (21) and by ANOVA-264 
simultaneous component analysis (ASCA) (22) with factors time, treatment, and an 265 
interaction term. For ASCA a permutation test to each factor (x1000 permutations) 266 
provided a p-value (H0= the factor has no effect on the experimental outcome). A 267 
second dataset was derived (ratio between values at day 29 and day 1, logged) and 268 
analysed by PCA. One to fourteen scores were used as input for classification into 4 269 
groups (high monomeric flavanol dose, low monomeric flavanol dose, placebo and 270 
PC) by discriminant analysis (21). A permutation test (random attribution of each 271 
volunteer’s 4 measurements to 4 groups x1000 permutations) was used to generate 272 
a p-value (probability of getting the classification success rate obtained with the real 273 
groups if there was no structure to the data). All analyses were conducted in Matlab 274 
2015a (The Mathworks, Cambridge, UK) except for ASCA which was carried out with 275 




Study population 280 
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Of the forty-three participants randomized to treatment, forty two completed the trial 281 
(15 men and 27 women).  One participant withdrew part way through the first test 282 
period citing difficulties with study time commitments as the reason for withdrawal. 283 
No serious adverse events were reported during the trial. Figure 1 shows the flow of 284 
participants through the trial. Participant parameters at eligibility assessment were 285 
(mean ± SD, n=42): age 63 ± 7 years; BMI 25.9 ± 3.1 kg/m2; SBP 137 ± 10; DBP 80 286 
± 7 mmHg. Compliance to treatments was high with overall compliance of 99.7% 287 
(capsules taken as a proportion of intended total) and individual compliance of ≥ 288 
92%.  289 
 290 
Absorption of epicatechin and metabolites 291 
Plasma EC metabolites were not detected in the baseline samples collected prior to 292 
the start of any of the treatments. Mean plasma total EC metabolite concentrations 293 
2 h after ingestion of the low and high dose EC treatments were 3.51 ± 2.2 and 9.07 294 
± 4.71, µmol/L, respectively. The major metabolites were EC-monoglucuronides, EC-295 
monosulfates and methyl-EC-monosulfates. As expected, only trace amounts of EC 296 
metabolites were detected 2 h after ingestion of the PC treatment (mean plasma 297 
peak concentration, 0.01 µmol/L). EC metabolites were not detected in any of the 298 
samples collected after ingestion of the placebo treatment, demonstrating excellent 299 
adherence to the low flavanol diet by all participants. 300 
 301 
Effects of treatments on SBP and other markers of CVD risk 302 
Table 2 shows the mean values for the various biomarkers of CVD risk for all 303 
participants at the start of the trial. All values were within reported physiological 304 
ranges. At 2 h after the ingestion of different doses of apple flavanols, no significant 305 
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differences were observed in SBP, DBP (peripheral and aortic), plasma NO, 306 
cf_PWV, ba_PWV or AI between treatments and placebo control (Table 3). 307 
Furthermore, we did not observe significant differences in BP, arterial stiffness or the 308 
plasma biomarkers ET-1, NO reaction products, total cholesterol, HDL/LDL 309 
cholesterol, triglycerides, glucose, fructosamine or insulin after 4 weeks’ intervention 310 
(Table 4). Post-hoc analysis of the primary outcome data (sBP; SD of differences = 311 
5.69 mm Hg) showed that the study had a power of 80% to detect a difference of 312 
2.53 mm Hg (P<0.05) between placebo and any one of the other treatments. 313 
 314 
Effects of treatments on metabolic profiles 315 
Inter-individual differences in metabolite profiles were large relative to differences 316 
between profiles of a given individual measured for different treatments and time 317 
points (see PCA scores plot of individual metabolite profiles, Figure 2 A and 318 
supplemental Figure 1 A).  The change in profiles between the two time-points 319 
was, however, of a similar scale between individuals (see PCA scores plot for ratioed 320 
data, (d29 vs d1), Figure 2 B and supplemental Figure 1 B). However, the overall 321 
success rate of classification of the profiles into the four treatment groups was no 322 
higher than would be expected by chance (p >0.1). Moreover, in the multivariate 323 
analysis of variance ASCA neither time, treatment, or their interaction, was found to 324 
be significant (p=0.91, p=1, p=1 respectively). This suggested that none of the 325 






The main finding of this study was that, compared to a placebo control, there were 330 
no significant effects of consuming an EC-rich flavanol extract (at doses of 70 or 140 331 
mg monomeric flavanols/d) or a monomeric flavanol-depleted PC-rich extract either 332 
2 h after a single dose (acute) or after daily consumption for 28 days on SBP or any 333 
of the other biomarkers of cardiometabolic risk. The appearance of EC phase-2 334 
conjugates in plasma 2 h after ingestion of the EC-rich flavanol extracts 335 
demonstrates that the EC was effectively absorbed resulting in mean peak plasma 336 
concentrations in the 3-10 µmol/L range, which is in keeping with previous reports 337 
(19). Since the isolated PC treatment provided a dose of procyanidin equivalent to 338 
that for the high dose EC-rich flavanol extract, these data show that neither 339 
monomeric flavanols nor PC significantly affected any of the cardiometabolic 340 
biomarkers. Further, they confirm the findings of a previously published report which 341 
indicated that PC are not a source of monomeric flavanols (i.e. EC and catechin are 342 
not released during fermentation by the gut microbiota) (24). 343 
 Oligomeric PC have been shown to exert biological activity in vitro (17, 18) but 344 
their bioavailability is very limited, and only nM concentrations of dimers and 345 
occasionally trimers have been reported to appear in peripheral blood.  As far as we 346 
are aware, the current report is the first RCT describing the effects of isolated PC on 347 
biomarkers for CVD. The finding of no significant effects on any of the biomarkers 348 
assessed is consistent with the limited bioavailability of PC, although it is possible that 349 
PC can exert effects in the body via the absorption of gut microbiota-derived 350 
metabolites such as hydroxyphenyl-γ-valerolactones, phenylvaleric acids and 351 
hydroxyphenylacetic acids which may be more extensively absorbed (25, 26). 352 
Although the data presented here do not suggest that these gut microbiota-derived 353 
metabolites were effective in changing the biomarkers assessed in this study, further 354 
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research of their biological activities is warranted. As a group, the microbiota-derived 355 
ring fission products represent the most substantial form of EC metabolites in humans, 356 
accounting for 78% of the radiolabel absorbed and excreted in urine over the 48 hours 357 
following ingestion of a single dose of [2-14C]-(‒)-EC compared to 22% for epicatechin 358 
phase-2 conjugates (26).  359 
    Despite the lack of clinical effects of monomeric and oligomeric flavanols in this 360 
report, the BP-lowering effects of flavanol-rich foods and extracts has been reported 361 
for a significant number of human intervention trials, most commonly after 362 
consumption of cocoa and cocoa based products over various durations in both 363 
healthy and non-healthy populations. Several meta-analyses of these trials report 364 
significant mean reductions in SBP as follows; 5.9 (p = 0.0003) (4), 4.5 (p= <0.001) 365 
(6), 2.8 (p = 0.005) (27) and 4.7 (p = 0.002) mmHg (5). The largest net reduction in 366 
office SBP observed in our trial was 0.39 mmHg after 28 d ingestion of the apple 367 
extract containing a 70 mg dose of monomeric flavanols; this falls well short of the 368 
BP responses reported in meta-analyses, was not significant, and there was not an 369 
increased response at the higher dose. Aside from the differences in study design 370 
(e.g. hypertensive vs normotensive, dose and duration of intervention, food matrix 371 
etc.) which makes direct comparisons in systematic reviews challenging, it has been 372 
hypothesised that the ‘open label’ approach to the treatments in many of these trials 373 
(e.g. flavanol-rich dark chocolate vs flavanol poor white chocolate) has increased the 374 
potential for the observed reductions in BP to be an ‘exaggerated’ placebo effect. 375 
This is supported by the lack of effect observed in several trials after ingestion of a 376 
cocoa beverage, in which the control drink has been better able to facilitate a blinded 377 
approach to the treatment, and that the effects of cocoa intervention trials on BP 378 
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were weak and non-significant when sub-grouped to take account of the blinding of 379 
participants to the treatment (-0.71 mmHg, p = 0.54) (27). 380 
Ingestion of flavanol-rich foods and beverages has also been reported to cause 381 
improvements in other biomarkers of CVD risk. For example, meta-analyses of human 382 
intervention trials after cocoa and green tea supplementation have shown significant 383 
reductions in serum insulin (7) and LDL cholesterol (4, 28, 29). In the study reported 384 
here, the largest reduction in LDL cholesterol was 0.08 mmol/L after 28 d 385 
supplementation with the apple flavanol extract containing 70 mg of monomeric 386 
flavanols. This effect size is 2-3-fold less than the overall reductions observed in the 387 
reported meta-analyses of RCT’s, and is not significant. Similarly, in some trials cocoa 388 
ingestion has been shown to decrease plasma ET-1 and increase plasma NO reaction 389 
products (10, 30) and in a dose dependant manner (30). We previously reported a 390 
significant increase in plasma NO 6 h after ingestion of apple purees containing 25 391 
and 100 mg EC but not after 14 d ingestion (31). However, the magnitude of change in 392 
NO reaction products was similar for both doses of EC/flavanols, and there was not an 393 
associated effect on ET-1. Likewise, 4 weeks’ ingestion of a cocoa beverage 394 
containing as little as 64 mg EC/d has been reported to significantly reduce cf_PWV 395 
by 0.4 m/s (13) which is double the reduction of 0.2 m/s observed for the equivalent 396 
duration and dose of epicatechin ingested by participants in the study reported here.  397 
There is a contradiction between an increasing number of reports describing 398 
increases in flow mediated dilatation, reductions in BP and changes in other 399 
biomarkers caused by consumption of flavanol-rich complex foods and beverages, 400 
and in particular cocoa and cocoa products, and the more recent reports that show no 401 
significant effects of purified EC (19, 20, this report) and purified PC (this report) on 402 
these vascular biomarkers. Two alternative paradigms can be considered: Either (i) 403 
20 
 
the physiological effects of consuming cocoa / dark chocolate are caused by other 404 
components in cocoa and are not dependent on the flavanols or (ii) the flavanols are 405 
involved in causing these effects but only in combination with other components in 406 
cocoa. Cocoa contains other compounds such as sugar, fats and bioactive 407 
phytochemicals including the methylxanthines theobromine and caffeine, all of which 408 
have the potential to affect the physiological responses to consumption of cocoa 409 
products. Theobromine for example, is present in chocolate at concentrations up to 410 
1.4% by weight (32) and there is evidence that it has biological activity (33, 34), and 411 
the effects of caffeine are widely reported and include increasing FMD and BP and 412 
reducing insulin sensitivity (35, 36). Further, a recent report provides evidence from 413 
carefully controlled dietary intervention trials to support the supposition that cocoa 414 
flavanols work in combination with other cocoa components to affect BP, endothelial 415 
function and other vascular biomarkers (37). Sansone and colleagues show that cocoa 416 
flavanols alone significantly increased flow mediated dilatation (FMD) of the brachial 417 
artery but did not significantly decrease BP 2 h after consumption of the test drinks, 418 
whereas when administered in combination with methylxanthines, both FMD and DBP 419 
were improved, and the FMD increase was significantly higher than with cocoa 420 
flavanols alone. Methylxanthines alone did not significantly affect FMD, DBP or SBP. 421 
These recent findings (lack of effects of isolated monomeric and oligomeric PC on BP 422 
(15, 16) this report), and a recent report showing that cocoa flavanols were only 423 
effective in reducing BP when administered in combination with methylxanthines (37) 424 
serves as a reminder that foods are complex and contain numerous compounds, 425 
therefore, ascribing a physiological response to consumption of a complex food like 426 
cocoa to just one compound or class of compounds is somewhat naive. Although it 427 
could be argued that not using a complex food such as apples or cocoa as the 428 
21 
 
treatment was a weakness in the trial design, the appropriate placebo food products 429 
(apples and cocoa that are similar except they lack the flavanols) are not available. 430 
   431 
CONCLUSION 432 
Acute and chronic consumption of isolated apple monomeric flavanols and PC 433 
oligomers had no significant effect on BP, various other cardiometabolic biomarkers 434 
or the concentrations of circulating host metabolites in pre-hypertensive adults. 435 
These data do not support the notion that in isolation, monomeric flavanols and/or 436 
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High dose  
 
 
Low dose     PC 
(-)-Epicatechin 125.9  62.9    6.5
(+)-Catechin    14.0    7.0
dp2   80.0  40.0  10.3
dp3   31.6  15.8  14.3
dp4   11.4    5.7  21.9
dp5     4.2    2.1  23.7
dp6     2.3    1.2  19.1
dp7     1.2    0.6  12.7
dp8     0.0    0.0  10.3
dp9     0.0    0.0  10.4
dp10     0.0    0.0    7.4
Total procyanidins 130.7  65.4 130.1
Total flavanols 270.6 135.3 136.5
 
1 The apple flavanol treatments were High dose = 140 mg monomers + 130 mg PC; 
Low dose = 70 mg monomers + 65 mg PC; PC = 130 mg PC. (‒)-EC was the 
predominant monomer in the monomer rich extract (90% (‒)-EC, 10% (+)-catechin). 







Table 2. Subject characteristics and biomarkers of CVD risk at baseline (n=42) 
 
Measurement variable  Baseline value
Gender ratio (M/F)      15/27
BMI (kg/m2)    25.9 ± 3.11
Age (yr)   63.0 ± 7.0
Office SBP (mmHg)    121 ± 92
Office DBP (mmHg)      69 ± 7
Vicorder pSBP (mmHg)    128 ± 10.8
Vicorder pDBP (mmHg)      66 ± 5.4
Vicorder aSBP (mmHg)   126 ± 11
Vicorder aDBP (mmHg)     66 ± 6
Cf_PWV (m/s)     8.2 ± 1.3
Ba_PWV (m/s)   14.4 ± 1.9
AI (%) 26.8 ± 6.4
ET-1 (pg/mL)     1.1 ± 0.4
NO reaction products (µmol/L)   35.9 ± 17.0
Insulin (pmol/L)  39.8 ± 17.1
Glucose (mmol/L)     5.3 ± 0.5
Fructosamine (µmol/L) 252.2 ± 47.1
Total cholesterol (mmol/L)    6.2 ± 1.0
HDL_Cholesterol (mmol/L)   1.68 ± 0.52
LDL_Cholesterol (mmol/L)   3.91 ± 0.92
Triglycerides (mmol/L)   1.50 ± 0.95
 
1Data are presented as mean ± SD (all such values) 
2SBP measured at baseline was lower than that measured at eligibility assessment. 
This was expected because BP rises during the morning and baseline measurements 





Table 3.  Changes in biomarkers of CVD risk, 2 h after ingestion of treatments containing either a low dose of monomeric apple 














Office SBP (mmHg) 42  6.14 ± 5.49  7.08 ± 6.11   7.79 ± 7.81  7.15 ± 6.05 0.206 
Office DBP (mmHg) 42  3.03 ± 2.79  3.94 ± 3.92   2.91 ± 3.24  3.58 ± 2.74 0.444 
Vicorder pSBP (mmHg) 42  6.81 ± 7.12  7.36 ± 6.75   7.17 ± 6.53  6.13 ± 6.88 0.754 
Vicorder pDBP (mmHg) 42  1.91 ± 3.66  2.71 ± 3.51   1.81 ± 3.30  2.12 ± 3.28 0.849 
Vicorder aSBP (mmHg) 42  6.27 ± 7.03  6.92 ± 6.67   6.82 ± 6.61  5.86 ± 6.66 0.780 
Vicorder aDBP (mmHg) 42  1.76 ± 3.64 3.36 ± 5.16   1.46 ± 3.66  2.23 ± 3.31 0.381 
Cf_PWV (m/s) 42 -0.04 ± 0.57  0.11 ± 0.72  -0.15 ± 1.77  0.18 ± 0.70 0.531 
Ba_PWV (m/s) 42   0.35 ± 0.50  0.34 ± 0.60   0.43 ± 0.66  0.31 ± 0.68 0.869 
AI (%) 42  -0.33 ± 2.92 -1.19 ± 3.26  -0.95 ± 2.39 -1.04 ± 2.85 0.351 
NO reaction products (µM) 34  -4.98 ± 5.49 -4.67 ± 6.88  -3.78 ± 4.69 -5.73 ± 5.13 0.461 
 
1 Low dose = 70 mg monomers + 65 mg procyanidins; High dose = 140 mg monomers + 130 mg procyanidins; procyanidins = 6.5 
mg monomers + 130 mg procyanidins. Data are mean ± SD (all such values)  
2 P values were calculated from the post – pre-differences between the four treatments using repeated measures ANOVA after 





Table 4. Changes in biomarkers of CVD risk, 29 d after ingestion of treatments containing either a low dose of monomeric apple flavanols, a 
high dose of monomeric apple flavanols, oligomeric procyanidins or placebo1 
1 Low dose = 70 mg monomers + 65 mg procyanidins; High dose = 140 mg monomers + 130 mg procyanidins; procyanidins = 6.5 mg 
monomers + 130 mg procyanidins. Data are mean ± SD.  
2 P values were calculated form the post–pre-differences between the four treatments using repeated measures ANOVA after excluding 
subjects with an incomplete set of differences. (See on-line supporting material for actual values; supplemental Table 2) 







 Procyanidins  Placebo p-value2 
Office SBP (mmHg) 42 -0.39 ± 6.11  1.83 ± 6.62  2.54 ± 7.02  1.60 ± 5.04 0.076 
Office DBP (mmHg) 42 -0.19 ± 3.94  1.06 ± 4.43  0.77 ± 3.90  0.55 ± 3.57 0.501 
Vicorder pSBP (mmHg) 42 -1.36 ± 7.14  0.83 ± 7.72  2.07 ± 6.58  1.61 ± 7.50 0.283 
Vicorder pDBP (mmHg) 42 -0.61 ± 3.41  1.04 ± 4.43  0.81 ± 4.12  0.93 ± 3.01 0.536 
Vicorder aSBP (mmHg) 41 -1.44 ± 7.26  0.74 ± 7.71  2.44 ± 6.51  1.93 ± 7.33 0.155 
Vicorder aDBP (mmHg) 41 -0.54 ± 3.40  1.34 ± 5.11  0.68 ± 3.93  1.09 ± 3.03 0.565 
Cf_PWV (m/s) 42 -0.20 ± 0.67 -0.03 ± 0.53 -0.25 ± 1.74  0.03 ± 0.68 0.791 
Ba_PWV (m/s) 41 -0.02 ± 0.63  0.30 ± 0.73  0.17 ± 0.82  0.15 ± 0.60 0.057 
AI (%) 41  0.00 ± 2.35 -0.07 ± 2.88  0.24 ± 2.30  0.28 ± 2.60 0.786 
NO reaction products (µM) 34  2.40 ± 24.38  9.17 ± 30.19  4.36 ± 19.08  5.03 ± 18.94 0.234 
Endothelin-1 (pg/mL) 36 -0.01 ± 0.38  0.04 ± 0.38  0.09 ± 0.32  0.05 ± 0.29 0.289 
Insulin (pmol/L) 36 -2.40 ± 23.05 -5.14 ± 13.02 -4.28 ± 12.38 -1.57 ± 11.65 0.339 
Glucose (mmol/L) 34 -0.06 ± 0.31 -0.16 ± 0.30 -0.09 ± 0.25  0.01 ± 0.40 0.142 
Fructosamine (µmol/L) 33 -1.20 ± 16.79  2.03 ± 14.83  2.71 ± 12.66  2.57 ± 25.33 0.944 
Total cholesterol (mmol/L) 34 -0.13 ± 0.51 -0.01 ± 0.60 -0.03 ± 0.62 -0.05 ± 0.67 0.836 
LDL cholesterol (mmol/L) 34 -0.08 ± 0.53 -0.03 ± 0.46 -0.04 ± 0.56 -0.02 ± 0.53 0.971 
HDL cholesterol (mmol/L) 34 -0.03 ± 0.14  0.03 ± 0.18  0.02 ± 0.16  0.01 ± 0.25 0.674 





Figure 1. Flow of participants through trial. Of the 117 participants assessed for 
eligibility, 74 did not meet the inclusion criteria. Eligible participants (n=43) were 
allocated sequentially to a treatment sequence order that was pre-determined using a 
block randomization approach. 1 participant dropped out of the trial part way through 
the first treatment phase. 
 
Figure 2. Principal component analysis (PCA) for the metabolomic data for all 
participants and treatments, for both time points (A; n=32 x 4 treatments x 2-time 
points (day 1, day 29)) and for the ratio of post-to-pre-treatment (B; n=32 x 4 
treatments).  
Scores on the first two principal components are shown and the percentage variance 
accounted for by each component indicated on each axis. The circle represents low 
dose monomeric flavanol treatment, the square the high dose monomeric flavanol 
treatment, the triangle the placebo, and the star the procyanidin treatment. For (A), 
open symbols represent day 1 and closed symbols day 29 of the treatments. Six 
individuals are highlighted; the volunteer number is given and an ellipse shows the 
spread of scores for each participant) (See on-line supporting material for scores on 
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Supplemental Table 1. Differences in biomarkers of CVD risk 2h after ingestion of treatments containing either a low dose of 
monomeric apple flavanols, a high dose of monomeric apple flavanols, oligomeric procyanidins or placebo 
 
 










Low dose High dose Procyanidins Placebo 
0h 2h 0h 2h 0h 2h 0h 2h 
Office SBP (mmHg) 42  121 ± 10 127 ± 11  120 ± 10   127 ± 11   120 ± 9 128 ± 13   121 ± 9     128 ± 9 
Office DBP (mmHg) 42    69 ± 7 72 ± 7  68 ± 7   72 ± 7     68 ± 6 71 ± 7     69 ± 7  73 ± 7 
Vicorder pSBP (mmHg) 42  128 ± 11 134 ± 13  126 ± 10   134 ± 12   126 ± 10 133 ± 12   127 ± 9  133 ± 10 
Vicorder pDBP (mmHg) 42    66 ± 5 68 ± 6  66 ± 6   68 ± 6     66 ± 5 68 ± 6     66 ± 5  68 ± 5 
Vicorder aSBP (mmHg) 41  126 ± 11 132 ± 13  124 ± 10   131 ± 12   124 ± 10 131 ± 12   124 ± 9  130 ± 10 
Vicorder aDBP (mmHg) 41    65 ± 8 67 ± 9  65 ± 6   69 ± 6     65 ± 8 67 ± 8     66 ± 5  68 ± 5 
Cf_PWV (m/s) 42   8.2 ± 1.4   8.2 ± 1.4   8.1 ± 1.3    8.2 ± 1.4    8.3 ± 1.8 8.1 ± 1.5   8.1 ± 1.2  8.3 ± 1.5 
Ba_PWV (m/s) 42 14.4 ± 2.0   14.7 ± 2.0   14.3 ± 1.9   14.6 ± 2.1 14.2 ± 1.9  14.7 ± 1.9 14.5 ± 2.2 14.8 ± 2.2 
AI (%) 42    27 ± 6      26 ± 6      28 ± 7      26 ± 6    27 ± 6     26 ± 7    27 ± 6    26 ± 5 
Nitric oxide (µM) 34    40 ± 21      31 ± 12      37 ± 20      32 ± 16    34 ± 14     30 ± 12    36 ± 14    31 ± 10 
On line supporting material 
 
Supplemental Table 2. Differences in biomarkers of CVD risk, 29 d after ingestion of treatments containing either a low dose of 
monomeric apple flavanols, a high dose of monomeric apple flavanols, oligomeric procyanidins or placebo 




Low dose High dose Procyanidins Placebo 
0h d29 0h d29 0h d29 0h d29 
Office SBP (mmHg) 42    121 ± 10 121 ± 10  120 ± 10  122 ± 10     120 ± 9   123 ± 11 121 ± 9 123 ± 9 
Office DBP (mmHg) 42      69 ± 7 69 ± 7  68 ± 7  69 ± 7       68 ± 6   69 ± 7   69 ± 7  73 ± 8 
Vicorder pSBP (mmHg) 42    128 ± 11 126 ± 10  126 ± 10  127 ± 11  126 ± 10   128 ± 11     127 ± 9   128 ± 10 
Vicorder pDBP (mmHg) 42      66 ± 5 66 ± 6  66 ± 6  67 ± 6  66 ± 5   67 ± 6       66 ± 5   67 ± 5 
Vicorder aSBP (mmHg) 41    126 ± 11 124 ± 10  124 ± 10  125 ± 11  124 ± 10   126 ± 11     124 ± 9    126 ± 10 
Vicorder aDBP (mmHg) 41      65 ± 8 65 ± 9  65 ± 6  67 ± 6  65 ± 8   66 ± 8       66 ± 5    67 ± 5 
Cf_PWV (m/s) 42   8.2 ± 1.4   8.0 ± 1.4   8.1 ± 1.3   8.1 ± 1.4   8.3 ± 1.8   8.0 ± 1.4     8.1 ± 1.2    8.1 ± 1.4 
Ba_PWV (m/s) 41   14.4 ± 2.0   14.3 ± 2.1   14.3 ± 1.9   14.6 ± 2.3   14.2 ± 1.9   14.4 ± 2.1   14.5 ± 2.2   14.4 ± 2.0 
AI (%) 41      27 ± 6      27 ± 7      28 ± 7      27 ± 6      27 ± 6      27 ± 6      27 ± 6      27 ± 5 
Nitric oxide (µM) 34  40 ± 21      38 ± 20      37 ± 20      44 ± 31      34 ± 14      42 ± 36      36 ± 14      43 ± 24 
Endothelin-1 (pg/mL) 36   1.11 ± 0.40   1.09 ± 0.42   1.08 ± 0.42   1.10 ± 0.43   1.12 ± 0.61   1.12 ± 0.42   1.08 ± 0.39   1.13 ± 0.38 
Insulin (pmol/L) 36   41.0 ± 24.0   37.8 ± 20.9   40.9 ± 20.5   35.4 ± 17.7   40.0 ± 19.8   35.8 ± 18.3   40.4 ± 21.5   38.4 ± 18.8 
Glucose (mmol/L) 34     5.3 ± 0.5     5.3 ± 0.5     5.3 ± 0.5     5.3 ± 0.4     5.3 ± 0.4     5.2 ± 0.4     5.3 ± 0.5     5.3 ± 0.5 
Fructosamine (µmol/L) 33 254.5 ± 35.7 254.1 ± 37.1 253.9 ± 37.4 256.2 ± 38.0 254.0 ± 34.1 259.3 ± 37.8 253.6 ± 50.7 259.8 ± 40.6 
Total cholesterol (mmol/L) 34     6.2 ± 1.0     6.1 ± 1.1     6.2 ± 0.9     6.2 ± 1.0     6.1 ± 1.0     6.1 ± 1.0     6.2 ± 1.0     6.2 ± 1.1 
LDL cholesterol (mmol/L) 34     3.9 ± 0.9     3.8 ± 0.9     3.9 ± 0.9     3.9 ± 0.9     3.9 ± 0.9     3.8 ± 0.9     3.9 ± 1.0     3.9 ± 0.9 
HDL cholesterol (mmol/L) 34     1.7 ± 0.5     1.6 ± 0.5     1.7 ± 0.5     1.7 ± 0.5     1.7 ± 0.5     1.7 ± 0.5     1.7 ± 0.5     1.7 ± 0.5 
Triglycerides (mmol/L) 34     1.5 ± 0.7     1.4 ± 0.7     1.4 ± 0.6     1.3 ± 0.5     1.5 ± 0.8     1.3 ± 0.6     1.4 ± 0.9     1.4 ± 0.5 
List of compounds observed in the Metabolon metabolomics analysis
BIOCHEMICAL SUPER_PATHWAY SUB_PATHWAY
1,2-dilinoleoyl-GPC (18:2/18:2) Lipid Phosphatidylcholine (PC)
1,2-dipalmitoyl-GPC (16:0/16:0) Lipid Phosphatidylcholine (PC)
1,3,7-trimethylurate Xenobiotics Xanthine Metabolism
1,3-dimethylurate Xenobiotics Xanthine Metabolism
1,5-anhydroglucitol (1,5-AG) Carbohydrate Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
1,7-dimethylurate Xenobiotics Xanthine Metabolism
1-(1-enyl-oleoyl)-2-linoleoyl-GPE (P-18:1/18:2)* Lipid Lysoplasmalogen
1-(1-enyl-oleoyl)-GPE (P-18:1)* Lipid Lysoplasmalogen
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPC (P-16:0/20:4)* Lipid Plasmalogen
1-(1-enyl-palmitoyl)-2-arachidonoyl-GPE (P-16:0/20:4)* Lipid Plasmalogen
1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* Lipid Plasmalogen
1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2)* Lipid Plasmalogen
1-(1-enyl-palmitoyl)-2-oleoyl-GPC (P-16:0/18:1)* Lipid Plasmalogen
1-(1-enyl-palmitoyl)-2-oleoyl-GPE (P-16:0/18:1)* Lipid Plasmalogen
1-(1-enyl-palmitoyl)-2-palmitoleoyl-GPC (P-16:0/16:1)* Lipid Plasmalogen
1-(1-enyl-palmitoyl)-2-palmitoyl-GPC (P-16:0/16:0)* Lipid Plasmalogen
1-(1-enyl-palmitoyl)-GPC (P-16:0)* Lipid Lysoplasmalogen
1-(1-enyl-palmitoyl)-GPE (P-16:0)* Lipid Lysoplasmalogen
1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4)* Lipid Plasmalogen
1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2)* Lipid Plasmalogen
1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1) Lipid Plasmalogen
1-(1-enyl-stearoyl)-GPE (P-18:0)* Lipid Lysoplasmalogen
1-arachidonoyl-GPC (20:4n6)* Lipid Lysophospholipid
1-arachidonoyl-GPE (20:4n6)* Lipid Lysophospholipid
1-arachidonoyl-GPI (20:4)* Lipid Lysophospholipid
1-lignoceroyl-GPC (24:0) Lipid Lysophospholipid
1-linolenoyl-GPC (18:3)* Lipid Lysophospholipid
1-linoleoyl-2-arachidonoyl-GPC (18:2/20:4n6)* Lipid Phosphatidylcholine (PC)
1-linoleoyl-2-linolenoyl-GPC (18:2/18:3)* Lipid Phosphatidylcholine (PC)
1-linoleoyl-GPC (18:2) Lipid Lysophospholipid
1-linoleoyl-GPE (18:2)* Lipid Lysophospholipid
1-linoleoyl-GPI (18:2)* Lipid Lysophospholipid
1-methylguanidine Amino Acid Guanidino and Acetamido Metabolism
1-methylhistidine Amino Acid Histidine Metabolism
1-methylimidazoleacetate Amino Acid Histidine Metabolism
1-methylnicotinamide Cofactors and Vitamins Nicotinate and Nicotinamide Metabolism
1-methylurate Xenobiotics Xanthine Metabolism
1-methylxanthine Xenobiotics Xanthine Metabolism
1-oleoyl-2-arachidonoyl-GPE (18:1/20:4)* Lipid Phosphatidylethanolamine (PE)
1-oleoyl-2-linoleoyl-GPE (18:1/18:2)* Lipid Phosphatidylethanolamine (PE)
1-oleoyl-2-linoleoyl-GPI (18:1/18:2)* Lipid Phosphatidylinositol (PI)
1-oleoyl-GPC (18:1) Lipid Lysophospholipid
1-oleoyl-GPE (18:1) Lipid Lysophospholipid
1-oleoyl-GPI (18:1)* Lipid Lysophospholipid
1-palmitoleoyl-2-linolenoyl-GPC (16:1/18:3)* Lipid Phosphatidylcholine (PC)
1-palmitoleoyl-2-linoleoyl-GPC (16:1/18:2)* Lipid Phosphatidylcholine (PC)
1-palmitoleoyl-GPC (16:1)* Lipid Lysophospholipid
1-palmitoyl-2-arachidonoyl-GPC (16:0/20:4n6) Lipid Phosphatidylcholine (PC)
1-palmitoyl-2-arachidonoyl-GPE (16:0/20:4)* Lipid Phosphatidylethanolamine (PE)
1-palmitoyl-2-arachidonoyl-GPI (16:0/20:4)* Lipid Phosphatidylinositol (PI)
1-palmitoyl-2-gamma-linolenoyl-GPC (16:0/18:3n6)* Lipid Phosphatidylcholine (PC)
1-palmitoyl-2-linoleoyl-GPC (16:0/18:2) Lipid Phosphatidylcholine (PC)
1-palmitoyl-2-linoleoyl-GPE (16:0/18:2) Lipid Phosphatidylethanolamine (PE)
1-palmitoyl-2-oleoyl-GPC (16:0/18:1) Lipid Phosphatidylcholine (PC)
1-palmitoyl-2-oleoyl-GPE (16:0/18:1) Lipid Phosphatidylethanolamine (PE)
1-palmitoyl-2-oleoyl-GPI (16:0/18:1)* Lipid Phosphatidylinositol (PI)
1-palmitoyl-2-palmitoleoyl-GPC (16:0/16:1)* Lipid Phosphatidylcholine (PC)
1-palmitoyl-2-stearoyl-GPC (16:0/18:0) Lipid Phosphatidylcholine (PC)
1-palmitoyl-GPC (16:0) Lipid Lysophospholipid
1-palmitoyl-GPE (16:0) Lipid Lysophospholipid
1-palmitoyl-GPI (16:0) Lipid Lysophospholipid
1-stearoyl-2-arachidonoyl-GPC (18:0/20:4) Lipid Phosphatidylcholine (PC)
1-stearoyl-2-arachidonoyl-GPE (18:0/20:4) Lipid Phosphatidylethanolamine (PE)
1-stearoyl-2-arachidonoyl-GPI (18:0/20:4) Lipid Phosphatidylinositol (PI)
1-stearoyl-2-arachidonoyl-GPS (18:0/20:4) Lipid Phosphatidylserine (PS)
1-stearoyl-2-linoleoyl-GPC (18:0/18:2)* Lipid Phosphatidylcholine (PC)
1-stearoyl-2-linoleoyl-GPE (18:0/18:2)* Lipid Phosphatidylethanolamine (PE)
1-stearoyl-2-linoleoyl-GPI (18:0/18:2) Lipid Phosphatidylinositol (PI)
1-stearoyl-2-oleoyl-GPC (18:0/18:1) Lipid Phosphatidylcholine (PC)
1-stearoyl-2-oleoyl-GPE (18:0/18:1) Lipid Phosphatidylethanolamine (PE)
1-stearoyl-2-oleoyl-GPI (18:0/18:1)* Lipid Phosphatidylinositol (PI)
1-stearoyl-2-oleoyl-GPS (18:0/18:1) Lipid Phosphatidylserine (PS)
1-stearoyl-GPC (18:0) Lipid Lysophospholipid
1-stearoyl-GPE (18:0) Lipid Lysophospholipid
1-stearoyl-GPI (18:0) Lipid Lysophospholipid
10-undecenoate (11:1n1) Lipid Medium Chain Fatty Acid
13-HODE + 9-HODE Lipid Fatty Acid, Monohydroxy
ONLINE SUPPLEMENTAL MATERIAL
16a-hydroxy DHEA 3-sulfate Lipid Steroid
18-hydroxycorticosterone Lipid Steroid
2'-deoxyuridine Nucleotide Pyrimidine Metabolism, Uracil containing
2'-O-methylcytidine Nucleotide Pyrimidine Metabolism, Cytidine containing
2'-O-methyluridine Nucleotide Pyrimidine Metabolism, Uracil containing
2,3-dihydroxy-2-methylbutyrate Amino Acid Leucine, Isoleucine and Valine Metabolism
2,3-dihydroxyisovalerate Xenobiotics Food Component/Plant
2-acetamidophenol sulfate Xenobiotics Drug
2-aminoadipate Amino Acid Lysine Metabolism
2-aminobutyrate Amino Acid Glutathione Metabolism
2-aminoheptanoate Lipid Fatty Acid, Amino
2-aminooctanoate Lipid Fatty Acid, Amino
2-aminophenol sulfate Xenobiotics Chemical
2-hydroxy-3-methylvalerate Amino Acid Leucine, Isoleucine and Valine Metabolism
2-hydroxyacetaminophen sulfate* Xenobiotics Drug
2-hydroxybutyrate/2-hydroxyisobutyrate Amino Acid Glutathione Metabolism
2-hydroxyglutarate Lipid Fatty Acid, Dicarboxylate
2-hydroxyhippurate (salicylurate) Xenobiotics Benzoate Metabolism
2-hydroxyibuprofen Xenobiotics Drug
2-hydroxyoctanoate Lipid Fatty Acid, Monohydroxy
2-hydroxyphenylacetate Amino Acid Tyrosine Metabolism
2-methoxyacetaminophen glucuronide* Xenobiotics Drug
2-methoxyacetaminophen sulfate* Xenobiotics Drug
2-methoxyresorcinol sulfate Xenobiotics Chemical
2-methylbutyrylcarnitine (C5) Amino Acid Leucine, Isoleucine and Valine Metabolism
2-methylbutyrylglycine Amino Acid Leucine, Isoleucine and Valine Metabolism
2-oxindole-3-acetate Xenobiotics Food Component/Plant
2-oxoarginine* Amino Acid Urea cycle; Arginine and Proline Metabolism
2-palmitoyl-GPC (16:0)* Lipid Lysophospholipid
2-piperidinone Xenobiotics Food Component/Plant
2-stearoyl-GPE (18:0)* Lipid Lysophospholipid
21-hydroxypregnenolone disulfate Lipid Steroid
3,7-dimethylurate Xenobiotics Xanthine Metabolism
3-(3-hydroxyphenyl)propionate Xenobiotics Benzoate Metabolism
3-(4-hydroxyphenyl)lactate Amino Acid Tyrosine Metabolism
3-(cystein-S-yl)acetaminophen* Xenobiotics Drug
3-(N-acetyl-L-cystein-S-yl) acetaminophen Xenobiotics Drug
3-aminoisobutyrate Nucleotide Pyrimidine Metabolism, Thymine containing
3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF) Lipid Fatty Acid, Dicarboxylate
3-hydroxy-2-ethylpropionate Amino Acid Leucine, Isoleucine and Valine Metabolism
3-hydroxy-3-methylglutarate Lipid Mevalonate Metabolism
3-hydroxybutyrate (BHBA) Lipid Ketone Bodies
3-hydroxybutyrylcarnitine (1) Lipid Fatty Acid Metabolism(Acyl Carnitine)
3-hydroxybutyrylcarnitine (2) Lipid Fatty Acid Metabolism(Acyl Carnitine)
3-hydroxyhexanoate Lipid Fatty Acid, Monohydroxy
3-hydroxyhippurate Xenobiotics Benzoate Metabolism
3-hydroxyisobutyrate Amino Acid Leucine, Isoleucine and Valine Metabolism
3-hydroxyoctanoate Lipid Fatty Acid, Monohydroxy
3-hydroxypyridine sulfate Xenobiotics Chemical
3-hydroxyquinine Xenobiotics Drug
3-indoxyl sulfate Amino Acid Tryptophan Metabolism
3-methoxycatechol sulfate (1) Xenobiotics Benzoate Metabolism
3-methoxytyrosine Amino Acid Tyrosine Metabolism
3-methyl catechol sulfate (1) Xenobiotics Benzoate Metabolism
3-methyl-2-oxobutyrate Amino Acid Leucine, Isoleucine and Valine Metabolism
3-methyl-2-oxovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism
3-methyladipate Lipid Fatty Acid, Dicarboxylate
3-methylcytidine Nucleotide Pyrimidine Metabolism, Cytidine containing
3-methylglutaconate Amino Acid Leucine, Isoleucine and Valine Metabolism
3-methylglutarylcarnitine (2) Amino Acid Leucine, Isoleucine and Valine Metabolism
3-methylhistidine Amino Acid Histidine Metabolism
3-methylxanthine Xenobiotics Xanthine Metabolism
3-phenylpropionate (hydrocinnamate) Xenobiotics Benzoate Metabolism
3-ureidopropionate Nucleotide Pyrimidine Metabolism, Uracil containing
3beta-hydroxy-5-cholestenoate Lipid Sterol
4-acetamidobutanoate Amino Acid Polyamine Metabolism
4-acetamidophenol Xenobiotics Drug
4-acetamidophenylglucuronide Xenobiotics Drug
4-acetaminophen sulfate Xenobiotics Drug
4-allylphenol sulfate Xenobiotics Food Component/Plant
4-aminophenol sulfate (2) Xenobiotics Drug
4-cholesten-3-one Lipid Sterol
4-ethylphenylsulfate Xenobiotics Benzoate Metabolism
4-guanidinobutanoate Amino Acid Guanidino and Acetamido Metabolism
4-hydroxychlorothalonil Xenobiotics Chemical
4-hydroxycinnamate sulfate Amino Acid Tyrosine Metabolism
4-hydroxycoumarin Xenobiotics Drug
4-hydroxyglutamate Amino Acid Glutamate Metabolism
4-hydroxyhippurate Xenobiotics Benzoate Metabolism
4-hydroxyphenylacetylglutamine Peptide Acetylated Peptides
4-methyl-2-oxopentanoate Amino Acid Leucine, Isoleucine and Valine Metabolism
4-methylcatechol sulfate Xenobiotics Benzoate Metabolism
4-vinylphenol sulfate Xenobiotics Benzoate Metabolism
5,6-dihydrothymine Nucleotide Pyrimidine Metabolism, Thymine containing
5,6-dihydrouracil Nucleotide Pyrimidine Metabolism, Uracil containing
5-(galactosylhydroxy)-L-lysine Amino Acid Lysine Metabolism
5-acetylamino-6-amino-3-methyluracil Xenobiotics Xanthine Metabolism
5-acetylamino-6-formylamino-3-methyluracil Xenobiotics Xanthine Metabolism
5-bromotryptophan Amino Acid Tryptophan Metabolism
5-hydroxyhexanoate Lipid Fatty Acid, Monohydroxy
5-hydroxylysine Amino Acid Lysine Metabolism
5-methylthioadenosine (MTA) Amino Acid Polyamine Metabolism
5-methyluridine (ribothymidine) Nucleotide Pyrimidine Metabolism, Uracil containing
5-oxoproline Amino Acid Glutathione Metabolism
5alpha-androstan-3alpha,17beta-diol disulfate Lipid Steroid
5alpha-androstan-3alpha,17beta-diol monosulfate (1) Lipid Steroid
5alpha-androstan-3alpha,17beta-diol monosulfate (2) Lipid Steroid
5alpha-androstan-3beta,17alpha-diol disulfate Lipid Steroid
5alpha-androstan-3beta,17beta-diol disulfate Lipid Steroid
5alpha-androstan-3beta,17beta-diol monosulfate (2) Lipid Steroid
5alpha-pregnan-3beta,20alpha-diol disulfate Lipid Steroid
5alpha-pregnan-3beta,20alpha-diol monosulfate (2) Lipid Steroid
5alpha-pregnan-3beta,20beta-diol monosulfate (1) Lipid Steroid
6-hydroxyindole sulfate Xenobiotics Chemical
6-oxopiperidine-2-carboxylate Amino Acid Lysine Metabolism
7-alpha-hydroxy-3-oxo-4-cholestenoate (7-Hoca) Lipid Sterol
7-methylguanine Nucleotide Purine Metabolism, Guanine containing
7-methylurate Xenobiotics Xanthine Metabolism
7-methylxanthine Xenobiotics Xanthine Metabolism
acesulfame Xenobiotics Food Component/Plant
acetylcarnitine (C2) Lipid Fatty Acid Metabolism(Acyl Carnitine)
acisoga Amino Acid Polyamine Metabolism
aconitate [cis or trans] Energy TCA Cycle
adenine Nucleotide Purine Metabolism, Adenine containing
adenosine 3',5'-cyclic monophosphate (cAMP) Nucleotide Purine Metabolism, Adenine containing
adenosine 5'-monophosphate (AMP) Nucleotide Purine Metabolism, Adenine containing
adipoylcarnitine (C6-DC) Lipid Fatty Acid Metabolism(Acyl Carnitine)
adrenate (22:4n6) Lipid Polyunsaturated Fatty Acid (n3 and n6)
adrenoylcarnitine (C22:4)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
alanine Amino Acid Alanine and Aspartate Metabolism
allantoin Nucleotide Purine Metabolism, (Hypo)Xanthine/Inosine containing
alliin Xenobiotics Food Component/Plant
alpha-hydroxyisocaproate Amino Acid Leucine, Isoleucine and Valine Metabolism
alpha-hydroxyisovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism
alpha-ketobutyrate Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
alpha-ketoglutarate Energy TCA Cycle
alpha-tocopherol Cofactors and Vitamins Tocopherol Metabolism
andro steroid monosulfate (1)* Lipid Steroid
androstenediol (3alpha, 17alpha) monsulfate (2) Lipid Steroid
androstenediol (3alpha, 17alpha) monsulfate (3) Lipid Steroid
androstenediol (3beta,17beta) disulfate (1) Lipid Steroid
androstenediol (3beta,17beta) disulfate (2) Lipid Steroid
androstenediol (3beta,17beta) monosulfate (1) Lipid Steroid
androstenediol (3beta,17beta) monosulfate (2) Lipid Steroid
androsterone sulfate Lipid Steroid
arabinose Carbohydrate Pentose Metabolism
arabitol/xylitol Carbohydrate Pentose Metabolism
arabonate/xylonate Carbohydrate Pentose Metabolism
arachidonate (20:4n6) Lipid Polyunsaturated Fatty Acid (n3 and n6)
arachidonoylcarnitine (C20:4) Lipid Fatty Acid Metabolism(Acyl Carnitine)
arachidonoylcholine Lipid Fatty Acid Metabolism (Acyl Choline)
arachidoylcarnitine (C20)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
argininate* Amino Acid Urea cycle; Arginine and Proline Metabolism
arginine Amino Acid Urea cycle; Arginine and Proline Metabolism
asparagine Amino Acid Alanine and Aspartate Metabolism
aspartate Amino Acid Alanine and Aspartate Metabolism
behenoyl dihydrosphingomyelin (d18:0/22:0)* Lipid Sphingolipid Metabolism
behenoyl sphingomyelin (d18:1/22:0)* Lipid Sphingolipid Metabolism
behenoylcarnitine (C22)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
benzoate Xenobiotics Benzoate Metabolism
benzoylcarnitine* Xenobiotics Chemical
beta-citrylglutamate Amino Acid Glutamate Metabolism
beta-cryptoxanthin Xenobiotics Food Component/Plant
beta-guanidinopropanoate Xenobiotics Food Component/Plant
beta-hydroxyisovalerate Amino Acid Leucine, Isoleucine and Valine Metabolism
beta-sitosterol Lipid Sterol
betaine Amino Acid Glycine, Serine and Threonine Metabolism
betonicine Xenobiotics Food Component/Plant
bilirubin (E,E)* Cofactors and Vitamins Hemoglobin and Porphyrin Metabolism
bilirubin (E,Z or Z,E)* Cofactors and Vitamins Hemoglobin and Porphyrin Metabolism
bilirubin (Z,Z) Cofactors and Vitamins Hemoglobin and Porphyrin Metabolism
biliverdin Cofactors and Vitamins Hemoglobin and Porphyrin Metabolism
butyrylcarnitine (C4) Lipid Fatty Acid Metabolism (also BCAA Metabolism)
C-glycosyltryptophan Amino Acid Tryptophan Metabolism
caffeic acid sulfate Xenobiotics Xanthine Metabolism
caffeine Xenobiotics Xanthine Metabolism
campesterol Lipid Sterol
caproate (6:0) Lipid Medium Chain Fatty Acid
caprylate (8:0) Lipid Medium Chain Fatty Acid
carboxyethyl-GABA Amino Acid Glutamate Metabolism
carboxyibuprofen Xenobiotics Drug
carnitine Lipid Carnitine Metabolism
carotene diol (1) Xenobiotics Food Component/Plant
carotene diol (2) Xenobiotics Food Component/Plant
carotene diol (3) Xenobiotics Food Component/Plant
catechol sulfate Xenobiotics Benzoate Metabolism
ceramide (d18:1/14:0, d16:1/16:0)* Lipid Ceramides
ceramide (d18:1/17:0, d17:1/18:0)* Lipid Ceramides
ceramide (d18:1/20:0, d16:1/22:0, d20:1/18:0)* Lipid Ceramides
cerotoylcarnitine (C26)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
cetirizine Xenobiotics Drug
chenodeoxycholate Lipid Primary Bile Acid Metabolism
chiro-inositol Lipid Inositol Metabolism
cholate Lipid Primary Bile Acid Metabolism
cholesterol Lipid Sterol
choline Lipid Phospholipid Metabolism
choline phosphate Lipid Phospholipid Metabolism
cinnamoylglycine Xenobiotics Food Component/Plant
cis-4-decenoylcarnitine (C10:1) Lipid Fatty Acid Metabolism(Acyl Carnitine)
citrate Energy TCA Cycle
citrulline Amino Acid Urea cycle; Arginine and Proline Metabolism
cortisol Lipid Steroid
cortisone Lipid Steroid
creatine Amino Acid Creatine Metabolism
creatinine Amino Acid Creatine Metabolism
cys-gly, oxidized Amino Acid Glutathione Metabolism
cystathionine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
cysteine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
cysteine s-sulfate Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
cysteine sulfinic acid Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
cysteine-glutathione disulfide Amino Acid Glutathione Metabolism
cysteinylglycine Amino Acid Glutathione Metabolism
cystine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
cytidine Nucleotide Pyrimidine Metabolism, Cytidine containing
decanoylcarnitine (C10) Lipid Fatty Acid Metabolism(Acyl Carnitine)
dehydroisoandrosterone sulfate (DHEA-S) Lipid Steroid
deoxycarnitine Lipid Carnitine Metabolism
deoxycholate Lipid Secondary Bile Acid Metabolism
desmethylnaproxen Xenobiotics Drug
desmethylnaproxen sulfate Xenobiotics Drug
diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [1]* Lipid Diacylglycerol
diacylglycerol (12:0/18:1, 14:0/16:1, 16:0/14:1) [2]* Lipid Diacylglycerol
diacylglycerol (14:0/18:1, 16:0/16:1) [1]* Lipid Diacylglycerol
diacylglycerol (14:0/18:1, 16:0/16:1) [2]* Lipid Diacylglycerol
diacylglycerol (16:1/18:2 [2], 16:0/18:3 [1])* Lipid Diacylglycerol
dihomo-linolenate (20:3n3 or n6) Lipid Polyunsaturated Fatty Acid (n3 and n6)
dihomo-linolenoyl-choline Lipid Fatty Acid Metabolism (Acyl Choline)
dihomo-linolenoylcarnitine (20:3n3 or 6)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
dihomo-linoleoylcarnitine (C20:2)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
dihydroorotate Nucleotide Pyrimidine Metabolism, Orotate containing
dimethyl sulfone Xenobiotics Chemical
dimethylarginine (SDMA + ADMA) Amino Acid Urea cycle; Arginine and Proline Metabolism
dimethylglycine Amino Acid Glycine, Serine and Threonine Metabolism
docosahexaenoate (DHA; 22:6n3) Lipid Polyunsaturated Fatty Acid (n3 and n6)
docosahexaenoylcarnitine (C22:6)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
docosahexaenoylcholine Lipid Fatty Acid Metabolism (Acyl Choline)
docosapentaenoate (n3 DPA; 22:5n3) Lipid Polyunsaturated Fatty Acid (n3 and n6)
docosapentaenoylcarnitine (C22:5n3)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
docosatrienoate (22:3n3) Lipid Polyunsaturated Fatty Acid (n3 and n6)
dodecanedioate Lipid Fatty Acid, Dicarboxylate
dopamine 3-O-sulfate Amino Acid Tyrosine Metabolism
DSGEGDFXAEGGGVR* Peptide Fibrinogen Cleavage Peptide
ectoine Xenobiotics Chemical
EDTA Xenobiotics Chemical
eicosapentaenoate (EPA; 20:5n3) Lipid Polyunsaturated Fatty Acid (n3 and n6)
eicosapentaenoylcholine Lipid Fatty Acid Metabolism (Acyl Choline)
eicosenoate (20:1) Lipid Long Chain Fatty Acid
eicosenoylcarnitine (C20:1)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
epiandrosterone sulfate Lipid Steroid
ergothioneine Xenobiotics Food Component/Plant
erythritol Xenobiotics Food Component/Plant
erythronate* Carbohydrate Aminosugar Metabolism
ethyl glucuronide Xenobiotics Chemical
ethyl paraben sulfate Xenobiotics Chemical
ethylmalonate Amino Acid Leucine, Isoleucine and Valine Metabolism
etiocholanolone glucuronide Lipid Steroid
eugenol sulfate Xenobiotics Food Component/Plant
formiminoglutamate Amino Acid Histidine Metabolism
fructose Carbohydrate Fructose, Mannose and Galactose Metabolism
gamma-carboxyglutamate Amino Acid Glutamate Metabolism
gamma-CEHC Cofactors and Vitamins Tocopherol Metabolism
gamma-glutamyl-2-aminobutyrate Peptide Gamma-glutamyl Amino Acid
gamma-glutamyl-alpha-lysine Peptide Gamma-glutamyl Amino Acid
gamma-glutamyl-epsilon-lysine Peptide Gamma-glutamyl Amino Acid
gamma-glutamylalanine Peptide Gamma-glutamyl Amino Acid
gamma-glutamylglutamate Peptide Gamma-glutamyl Amino Acid
gamma-glutamylglutamine Peptide Gamma-glutamyl Amino Acid
gamma-glutamylglycine Peptide Gamma-glutamyl Amino Acid
gamma-glutamylhistidine Peptide Gamma-glutamyl Amino Acid
gamma-glutamylisoleucine* Peptide Gamma-glutamyl Amino Acid
gamma-glutamylleucine Peptide Gamma-glutamyl Amino Acid
gamma-glutamylmethionine Peptide Gamma-glutamyl Amino Acid
gamma-glutamylphenylalanine Peptide Gamma-glutamyl Amino Acid
gamma-glutamylthreonine Peptide Gamma-glutamyl Amino Acid
gamma-glutamyltryptophan Peptide Gamma-glutamyl Amino Acid
gamma-glutamyltyrosine Peptide Gamma-glutamyl Amino Acid
gamma-glutamylvaline Peptide Gamma-glutamyl Amino Acid
gamma-tocopherol/beta-tocopherol Cofactors and Vitamins Tocopherol Metabolism
gentisate Amino Acid Tyrosine Metabolism
gluconate Xenobiotics Food Component/Plant
glucose Carbohydrate Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
glucuronate Carbohydrate Aminosugar Metabolism
glutamate Amino Acid Glutamate Metabolism
glutamine Amino Acid Glutamate Metabolism
glutarylcarnitine (C5-DC) Amino Acid Lysine Metabolism
glycerate Carbohydrate Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
glycerol Lipid Glycerolipid Metabolism
glycerol 3-phosphate Lipid Glycerolipid Metabolism
glycerophosphoethanolamine Lipid Phospholipid Metabolism
glycerophosphoglycerol Lipid Glycerolipid Metabolism
glycerophosphoinositol* Lipid Phospholipid Metabolism
glycerophosphorylcholine (GPC) Lipid Phospholipid Metabolism
glycine Amino Acid Glycine, Serine and Threonine Metabolism
glycochenodeoxycholate Lipid Primary Bile Acid Metabolism
glycochenodeoxycholate glucuronide (1) Lipid Primary Bile Acid Metabolism
glycochenodeoxycholate sulfate Lipid Primary Bile Acid Metabolism
glycocholate Lipid Primary Bile Acid Metabolism
glycocholenate sulfate* Lipid Secondary Bile Acid Metabolism
glycodeoxycholate Lipid Secondary Bile Acid Metabolism
glycodeoxycholate sulfate Lipid Secondary Bile Acid Metabolism
glycolithocholate sulfate* Lipid Secondary Bile Acid Metabolism
glycosyl ceramide (d18:1/20:0, d16:1/22:0)* Lipid Ceramides
glycosyl ceramide (d18:1/23:1, d17:1/24:1)* Lipid Ceramides
glycosyl-N-behenoyl-sphingadienine (d18:2/22:0)* Lipid Sphingolipid Metabolism
glycosyl-N-palmitoyl-sphingosine (d18:1/16:0) Lipid Sphingolipid Metabolism
glycosyl-N-stearoyl-sphingosine (d18:1/18:0) Lipid Sphingolipid Metabolism
glycoursodeoxycholate Lipid Secondary Bile Acid Metabolism
guanidinoacetate Amino Acid Creatine Metabolism
guanosine Nucleotide Purine Metabolism, Guanine containing
gulonate* Cofactors and Vitamins Ascorbate and Aldarate Metabolism
heptanoate (7:0) Lipid Medium Chain Fatty Acid
hexanoylcarnitine (C6) Lipid Fatty Acid Metabolism(Acyl Carnitine)
hexanoylglutamine Lipid Fatty Acid Metabolism (Acyl Glutamine)
hippurate Xenobiotics Benzoate Metabolism
histidine Amino Acid Histidine Metabolism
homoarginine Amino Acid Urea cycle; Arginine and Proline Metabolism
homocitrulline Amino Acid Urea cycle; Arginine and Proline Metabolism
homostachydrine* Xenobiotics Food Component/Plant
hydantoin-5-propionic acid Amino Acid Histidine Metabolism
hydroquinone sulfate Xenobiotics Drug
hyocholate Lipid Secondary Bile Acid Metabolism
hypotaurine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
hypoxanthine Nucleotide Purine Metabolism, (Hypo)Xanthine/Inosine containing
ibuprofen Xenobiotics Drug
ibuprofen acyl glucuronide Xenobiotics Drug
imidazole lactate Amino Acid Histidine Metabolism
imidazole propionate Amino Acid Histidine Metabolism
iminodiacetate (IDA) Xenobiotics Chemical
indoleacetate Amino Acid Tryptophan Metabolism
indoleacetylglutamine Amino Acid Tryptophan Metabolism
indolelactate Amino Acid Tryptophan Metabolism
indolepropionate Amino Acid Tryptophan Metabolism
indolin-2-one Xenobiotics Food Component/Plant
inosine Nucleotide Purine Metabolism, (Hypo)Xanthine/Inosine containing
isobutyrylcarnitine (C4) Amino Acid Leucine, Isoleucine and Valine Metabolism
isobutyrylglycine Amino Acid Leucine, Isoleucine and Valine Metabolism
isoleucine Amino Acid Leucine, Isoleucine and Valine Metabolism
isoursodeoxycholate Lipid Secondary Bile Acid Metabolism
isovalerylcarnitine (C5) Amino Acid Leucine, Isoleucine and Valine Metabolism
isovalerylglycine Amino Acid Leucine, Isoleucine and Valine Metabolism
kynurenate Amino Acid Tryptophan Metabolism
kynurenine Amino Acid Tryptophan Metabolism
L-urobilin Cofactors and Vitamins Hemoglobin and Porphyrin Metabolism
lactate Carbohydrate Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
lactosyl-N-nervonoyl-sphingosine (d18:1/24:1)* Lipid Sphingolipid Metabolism
lactosyl-N-palmitoyl-sphingosine (d18:1/16:0) Lipid Sphingolipid Metabolism
lanthionine Xenobiotics Chemical
laurylcarnitine (C12) Lipid Fatty Acid Metabolism(Acyl Carnitine)
leucine Amino Acid Leucine, Isoleucine and Valine Metabolism
lignoceroyl sphingomyelin (d18:1/24:0) Lipid Sphingolipid Metabolism
lignoceroylcarnitine (C24)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
linoleate (18:2n6) Lipid Polyunsaturated Fatty Acid (n3 and n6)
linolenate [alpha or gamma; (18:3n3 or 6)] Lipid Polyunsaturated Fatty Acid (n3 and n6)
linolenoylcarnitine (C18:3)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
linoleoyl-arachidonoyl-glycerol (18:2/20:4) [1]* Lipid Diacylglycerol
linoleoyl-arachidonoyl-glycerol (18:2/20:4) [2]* Lipid Diacylglycerol
linoleoyl-docosahexaenoyl-glycerol (18:2/22:6) [2]* Lipid Diacylglycerol
linoleoyl-linolenoyl-glycerol (18:2/18:3) [2]* Lipid Diacylglycerol
linoleoyl-linoleoyl-glycerol (18:2/18:2) [1]* Lipid Diacylglycerol
linoleoylcarnitine (C18:2)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
linoleoylcholine* Lipid Fatty Acid Metabolism (Acyl Choline)
lysine Amino Acid Lysine Metabolism
malate Energy TCA Cycle
maleate Lipid Fatty Acid, Dicarboxylate
malonate Lipid Fatty Acid Synthesis
maltotriose Carbohydrate Glycogen Metabolism
mannitol/sorbitol Carbohydrate Fructose, Mannose and Galactose Metabolism
mannose Carbohydrate Fructose, Mannose and Galactose Metabolism
margaroylcarnitine* Lipid Fatty Acid Metabolism(Acyl Carnitine)
methionine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
methionine sulfone Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
methionine sulfoxide Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
methyl glucopyranoside (alpha + beta) Xenobiotics Food Component/Plant
methyl indole-3-acetate Xenobiotics Food Component/Plant
methyl-4-hydroxybenzoate sulfate Xenobiotics Benzoate Metabolism
methylsuccinate Amino Acid Leucine, Isoleucine and Valine Metabolism
myo-inositol Lipid Inositol Metabolism
myristoleoylcarnitine (C14:1)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
myristoyl dihydrosphingomyelin (d18:0/14:0)* Lipid Sphingolipid Metabolism
myristoylcarnitine (C14) Lipid Fatty Acid Metabolism(Acyl Carnitine)
N('1)-acetylspermidine Amino Acid Polyamine Metabolism
N-(2-furoyl)glycine Xenobiotics Food Component/Plant
N-acetyl-1-methylhistidine* Amino Acid Histidine Metabolism
N-acetyl-3-methylhistidine* Amino Acid Histidine Metabolism
N-acetyl-aspartyl-glutamate (NAAG) Amino Acid Glutamate Metabolism
N-acetyl-beta-alanine Nucleotide Pyrimidine Metabolism, Uracil containing
N-acetylalanine Amino Acid Alanine and Aspartate Metabolism
N-acetylalliin Xenobiotics Food Component/Plant
N-acetylarginine Amino Acid Urea cycle; Arginine and Proline Metabolism
N-acetylaspartate (NAA) Amino Acid Alanine and Aspartate Metabolism
N-acetylcarnosine Peptide Dipeptide Derivative
N-acetylcitrulline Amino Acid Urea cycle; Arginine and Proline Metabolism
N-acetylglucosamine/N-acetylgalactosamine Carbohydrate Aminosugar Metabolism
N-acetylglucosaminylasparagine Carbohydrate Aminosugar Metabolism
N-acetylglutamate Amino Acid Glutamate Metabolism
N-acetylglutamine Amino Acid Glutamate Metabolism
N-acetylglycine Amino Acid Glycine, Serine and Threonine Metabolism
N-acetylhistidine Amino Acid Histidine Metabolism
N-acetylkynurenine (2) Amino Acid Tryptophan Metabolism
N-acetylleucine Amino Acid Leucine, Isoleucine and Valine Metabolism
N-acetylmethionine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
N-acetylneuraminate Carbohydrate Aminosugar Metabolism
N-acetylphenylalanine Amino Acid Phenylalanine Metabolism
N-acetylproline Amino Acid Urea cycle; Arginine and Proline Metabolism
N-acetylputrescine Amino Acid Polyamine Metabolism
N-acetylserine Amino Acid Glycine, Serine and Threonine Metabolism
N-acetyltaurine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
N-acetylthreonine Amino Acid Glycine, Serine and Threonine Metabolism
N-acetyltryptophan Amino Acid Tryptophan Metabolism
N-acetyltyrosine Amino Acid Tyrosine Metabolism
N-acetylvaline Amino Acid Leucine, Isoleucine and Valine Metabolism
N-behenoyl-sphingadienine (d18:2/22:0)* Lipid Sphingolipid Metabolism
N-delta-acetylornithine Amino Acid Urea cycle; Arginine and Proline Metabolism
N-formylmethionine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
N-methylproline Amino Acid Urea cycle; Arginine and Proline Metabolism
N-methyltaurine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
N-nervonoyl-hexadecasphingosine (d16:1/24:1)* Lipid Sphingolipid Metabolism
N-nervonoyl-sphingadiene (d18:2/24:1)* Lipid Sphingolipid Metabolism
N-palmitoyl-sphinganine (d18:0/16:0) Lipid Sphingolipid Metabolism
N-palmitoyl-sphingosine (d18:1/16:0) Lipid Sphingolipid Metabolism
N-stearoyl-sphingosine (d18:1/18:0)* Lipid Sphingolipid Metabolism
N-trimethyl 5-aminovalerate Amino Acid Lysine Metabolism
N1-Methyl-2-pyridone-5-carboxamide Cofactors and Vitamins Nicotinate and Nicotinamide Metabolism
N1-Methyl-4-pyridone-3-carboxamide Cofactors and Vitamins Nicotinate and Nicotinamide Metabolism
N1-methyladenosine Nucleotide Purine Metabolism, Adenine containing
N1-methylinosine Nucleotide Purine Metabolism, (Hypo)Xanthine/Inosine containing
N2,N2-dimethylguanosine Nucleotide Purine Metabolism, Guanine containing
N2,N5-diacetylornithine Amino Acid Urea cycle; Arginine and Proline Metabolism
N6,N6,N6-trimethyllysine Amino Acid Lysine Metabolism
N6-acetyllysine Amino Acid Lysine Metabolism
N6-carbamoylthreonyladenosine Nucleotide Purine Metabolism, Adenine containing
N6-carboxymethyllysine Carbohydrate Advanced Glycation End-product
N6-methyladenosine Nucleotide Purine Metabolism, Adenine containing
N6-succinyladenosine Nucleotide Purine Metabolism, Adenine containing
naproxen Xenobiotics Drug
nervonate (24:1n9)* Lipid Long Chain Fatty Acid
nervonoylcarnitine (C24:1)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
nicotinamide Cofactors and Vitamins Nicotinate and Nicotinamide Metabolism
O-acetylhomoserine Amino Acid Glycine, Serine and Threonine Metabolism
O-methylcatechol sulfate Xenobiotics Benzoate Metabolism
O-sulfo-L-tyrosine Xenobiotics Chemical
octanoylcarnitine (C8) Lipid Fatty Acid Metabolism(Acyl Carnitine)
oleate/vaccenate (18:1) Lipid Long Chain Fatty Acid
oleoyl ethanolamide Lipid Endocannabinoid
oleoyl-arachidonoyl-glycerol (18:1/20:4) [1]* Lipid Diacylglycerol
oleoyl-arachidonoyl-glycerol (18:1/20:4) [2]* Lipid Diacylglycerol
oleoyl-linolenoyl-glycerol (18:1/18:3) [2]* Lipid Diacylglycerol
oleoyl-linoleoyl-glycerol (18:1/18:2) [1] Lipid Diacylglycerol
oleoyl-linoleoyl-glycerol (18:1/18:2) [2] Lipid Diacylglycerol
oleoyl-oleoyl-glycerol (18:1/18:1)  [1]* Lipid Diacylglycerol
oleoyl-oleoyl-glycerol (18:1/18:1) [2]* Lipid Diacylglycerol
oleoylcarnitine (C18:1) Lipid Fatty Acid Metabolism(Acyl Carnitine)
oleoylcholine Lipid Fatty Acid Metabolism (Acyl Choline)
ornithine Amino Acid Urea cycle; Arginine and Proline Metabolism
orotate Nucleotide Pyrimidine Metabolism, Orotate containing
orotidine Nucleotide Pyrimidine Metabolism, Orotate containing
oxalate (ethanedioate) Cofactors and Vitamins Ascorbate and Aldarate Metabolism
p-cresol sulfate Xenobiotics Benzoate Metabolism
p-cresol-glucuronide* Amino Acid Tyrosine Metabolism
palmitoleoyl-arachidonoyl-glycerol (16:1/20:4) [2]* Lipid Diacylglycerol
palmitoleoyl-linoleoyl-glycerol (16:1/18:2) [1]* Lipid Diacylglycerol
palmitoleoyl-oleoyl-glycerol (16:1/18:1) [1]* Lipid Diacylglycerol
palmitoleoylcarnitine (C16:1)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
palmitoloelycholine Lipid Fatty Acid Metabolism (Acyl Choline)
palmitoyl dihydrosphingomyelin (d18:0/16:0)* Lipid Sphingolipid Metabolism
palmitoyl sphingomyelin (d18:1/16:0) Lipid Sphingolipid Metabolism
palmitoyl-arachidonoyl-glycerol (16:0/20:4) [2]* Lipid Diacylglycerol
palmitoyl-linoleoyl-glycerol (16:0/18:2) [1]* Lipid Diacylglycerol
palmitoyl-linoleoyl-glycerol (16:0/18:2) [2]* Lipid Diacylglycerol
palmitoyl-myristoyl-glycerol (16:0/14:0) [2] Lipid Diacylglycerol
palmitoyl-oleoyl-glycerol (16:0/18:1) [1]* Lipid Diacylglycerol
palmitoyl-oleoyl-glycerol (16:0/18:1) [2]* Lipid Diacylglycerol
palmitoyl-palmitoyl-glycerol (16:0/16:0) [1]* Lipid Diacylglycerol
palmitoyl-palmitoyl-glycerol (16:0/16:0) [2]* Lipid Diacylglycerol
palmitoylcarnitine (C16) Lipid Fatty Acid Metabolism(Acyl Carnitine)
palmitoylcholine Lipid Fatty Acid Metabolism (Acyl Choline)
pantothenate Cofactors and Vitamins Pantothenate and CoA Metabolism
paraxanthine Xenobiotics Xanthine Metabolism
perfluorooctanesulfonic acid (PFOS) Xenobiotics Chemical
phenol sulfate Amino Acid Tyrosine Metabolism
phenylacetylcarnitine Peptide Acetylated Peptides
phenylacetylglutamate Peptide Acetylated Peptides
phenylacetylglutamine Peptide Acetylated Peptides
phenylalanine Amino Acid Phenylalanine Metabolism
phenyllactate (PLA) Amino Acid Phenylalanine Metabolism
phenylpyruvate Amino Acid Phenylalanine Metabolism
phosphate Energy Oxidative Phosphorylation
phosphoethanolamine Lipid Phospholipid Metabolism
picolinate Amino Acid Tryptophan Metabolism
pimeloylcarnitine/3-methyladipoylcarnitine (C7-DC) Lipid Fatty Acid Metabolism(Acyl Carnitine)
pipecolate Amino Acid Lysine Metabolism
piperine Xenobiotics Food Component/Plant
pregn steroid monosulfate* Lipid Steroid
pregnanediol-3-glucuronide Lipid Steroid
pregnen-diol disulfate* Lipid Steroid
pregnenolone sulfate Lipid Steroid
pro-hydroxy-pro Amino Acid Urea cycle; Arginine and Proline Metabolism
proline Amino Acid Urea cycle; Arginine and Proline Metabolism
prolylglycine Peptide Dipeptide
propionylcarnitine (C3) Lipid Fatty Acid Metabolism (also BCAA Metabolism)
propionylglycine Lipid Fatty Acid Metabolism (also BCAA Metabolism)
propyl 4-hydroxybenzoate sulfate Xenobiotics Benzoate Metabolism
pseudouridine Nucleotide Pyrimidine Metabolism, Uracil containing
pyridoxate Cofactors and Vitamins Vitamin B6 Metabolism
pyroglutamine* Amino Acid Glutamate Metabolism
pyrraline Xenobiotics Food Component/Plant
pyruvate Carbohydrate Glycolysis, Gluconeogenesis, and Pyruvate Metabolism
quinate Xenobiotics Food Component/Plant
quinine Xenobiotics Drug
quinolinate Cofactors and Vitamins Nicotinate and Nicotinamide Metabolism
retinal Xenobiotics Food Component/Plant
retinol (Vitamin A) Cofactors and Vitamins Vitamin A Metabolism
ribitol Carbohydrate Pentose Metabolism
ribonate Carbohydrate Pentose Metabolism
S-1-pyrroline-5-carboxylate Amino Acid Glutamate Metabolism
S-allylcysteine Xenobiotics Food Component/Plant
S-methylcysteine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
S-methylcysteine sulfoxide Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
S-methylmethionine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
saccharin Xenobiotics Food Component/Plant
salicylate Xenobiotics Drug
salicyluric glucuronide* Xenobiotics Drug
sarcosine Amino Acid Glycine, Serine and Threonine Metabolism
serine Amino Acid Glycine, Serine and Threonine Metabolism
serotonin Amino Acid Tryptophan Metabolism
sphinganine Lipid Sphingolipid Metabolism
sphinganine-1-phosphate Lipid Sphingolipid Metabolism
sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d17:2/16:0, d18:2/15:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:0/18:0, d19:0/17:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:0/20:0, d16:0/22:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/14:0, d16:1/16:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/17:0, d17:1/18:0, d19:1/16:0) Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/18:1, d18:2/18:0) Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/19:0, d19:1/18:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/20:0, d16:1/22:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/20:1, d18:2/20:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/20:2, d18:2/20:1, d16:1/22:2)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/22:2, d18:2/22:1, d16:1/24:2)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/24:1, d18:2/24:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:2/14:0, d18:1/14:1)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:2/16:0, d18:1/16:1)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:2/18:1)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:2/21:0, d16:2/23:0)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:2/23:1)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:2/24:1, d18:1/24:2)* Lipid Sphingolipid Metabolism
sphingomyelin (d18:2/24:2)* Lipid Sphingolipid Metabolism
sphingosine Lipid Sphingolipid Metabolism
sphingosine 1-phosphate Lipid Sphingolipid Metabolism
stachydrine Xenobiotics Food Component/Plant
stearate (18:0) Lipid Long Chain Fatty Acid
stearidonate (18:4n3) Lipid Polyunsaturated Fatty Acid (n3 and n6)
stearoyl ethanolamide Lipid Endocannabinoid
stearoyl sphingomyelin (d18:1/18:0) Lipid Sphingolipid Metabolism
stearoyl-arachidonoyl-glycerol (18:0/20:4) [1]* Lipid Diacylglycerol
stearoyl-arachidonoyl-glycerol (18:0/20:4) [2]* Lipid Diacylglycerol
stearoylcarnitine (C18) Lipid Fatty Acid Metabolism(Acyl Carnitine)
stearoylcholine* Lipid Fatty Acid Metabolism (Acyl Choline)
suberoylcarnitine (C8-DC) Lipid Fatty Acid Metabolism(Acyl Carnitine)
succinate Energy TCA Cycle
succinimide Xenobiotics Chemical
succinylcarnitine (C4-DC) Energy TCA Cycle
sulfate* Xenobiotics Chemical
tartarate Xenobiotics Food Component/Plant
tartronate (hydroxymalonate) Xenobiotics Bacterial/Fungal
taurine Amino Acid Methionine, Cysteine, SAM and Taurine Metabolism
taurochenodeoxycholate Lipid Primary Bile Acid Metabolism
taurocholenate sulfate Lipid Secondary Bile Acid Metabolism
taurolithocholate 3-sulfate Lipid Secondary Bile Acid Metabolism
theanine Xenobiotics Food Component/Plant
theobromine Xenobiotics Xanthine Metabolism
theophylline Xenobiotics Xanthine Metabolism
thioproline Xenobiotics Chemical
threonate Cofactors and Vitamins Ascorbate and Aldarate Metabolism
threonine Amino Acid Glycine, Serine and Threonine Metabolism
thymol sulfate Xenobiotics Food Component/Plant
thyroxine Amino Acid Tyrosine Metabolism
tiglylcarnitine (C5:1-DC) Amino Acid Leucine, Isoleucine and Valine Metabolism
trans-4-hydroxyproline Amino Acid Urea cycle; Arginine and Proline Metabolism
trans-urocanate Amino Acid Histidine Metabolism
tricosanoyl sphingomyelin (d18:1/23:0)* Lipid Sphingolipid Metabolism
trigonelline (N'-methylnicotinate) Cofactors and Vitamins Nicotinate and Nicotinamide Metabolism
trimethylamine N-oxide Lipid Phospholipid Metabolism
tryptophan Amino Acid Tryptophan Metabolism
tryptophan betaine Amino Acid Tryptophan Metabolism
tyramine O-sulfate Amino Acid Tyrosine Metabolism
tyrosine Amino Acid Tyrosine Metabolism
umbelliferone sulfate Xenobiotics Food Component/Plant
uracil Nucleotide Pyrimidine Metabolism, Uracil containing
urate Nucleotide Purine Metabolism, (Hypo)Xanthine/Inosine containing
urea Amino Acid Urea cycle; Arginine and Proline Metabolism
uridine Nucleotide Pyrimidine Metabolism, Uracil containing
ursodeoxycholate Lipid Secondary Bile Acid Metabolism
valine Amino Acid Leucine, Isoleucine and Valine Metabolism
vanillactate Amino Acid Tyrosine Metabolism
vanillylmandelate (VMA) Amino Acid Tyrosine Metabolism
xanthine Nucleotide Purine Metabolism, (Hypo)Xanthine/Inosine containing
xanthurenate Amino Acid Tryptophan Metabolism
ximenoylcarnitine (C26:1)* Lipid Fatty Acid Metabolism(Acyl Carnitine)
xylose Carbohydrate Pentose Metabolism
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Supplemental Figure 1. Principal component analysis (PCA) for the metabolomic data for all volunteers and
treatments, for both �me-points (A; n=32 x 4 treatments x 2 �me-points (day 1, day 29)), and for the ra�o of
post- to pre-treatmemt (B; n=32 x 4 treatments). 
Scores on the third and fourth principal components are shown and the percentage variance accounted for 
by each component indicated on each axis. The circle represents the low dose monomeric flavonols treatment,
the square the high dose monomeric flavanols, the triangle the placebo, and the star the oligomeric procyanidins.
For (A), open symbols represent day 1 and closed symbols day 29 of the treatments. Six individuals are highlighted;
the volunteer number is given and an ellipse shows the spread of scores for each of these volunteers.
